Arbutus Short Term Debt from 2010 to 2024

ABUS Stock  USD 3.47  0.06  1.76%   
Arbutus Biopharma Short Term Debt yearly trend continues to be comparatively stable with very little volatility. Short Term Debt is likely to outpace its year average in 2024. From the period from 2010 to 2024, Arbutus Biopharma Short Term Debt quarterly data regression had r-value of (0.15) and coefficient of variation of  112.18. View All Fundamentals
 
Short Term Debt  
First Reported
2000-03-31
Previous Quarter
906 K
Current Value
468 K
Quarterly Volatility
2.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Arbutus Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arbutus Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 701.5 K or Selling General Administrative of 12.2 M, as well as many indicators such as Price To Sales Ratio of 13.01, Dividend Yield of 0.0529 or PTB Ratio of 3.72. Arbutus financial statements analysis is a perfect complement when working with Arbutus Biopharma Valuation or Volatility modules.
  
Check out the analysis of Arbutus Biopharma Correlation against competitors.

Latest Arbutus Biopharma's Short Term Debt Growth Pattern

Below is the plot of the Short Term Debt of Arbutus Biopharma Corp over the last few years. It is Arbutus Biopharma's Short Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arbutus Biopharma's overall financial position and show how it may be relating to other accounts over time.
Short Term Debt10 Years Trend
Pretty Stable
   Short Term Debt   
       Timeline  

Arbutus Short Term Debt Regression Statistics

Arithmetic Mean2,079,896
Geometric Mean0.00
Coefficient Of Variation112.18
Mean Deviation1,854,905
Median850,000
Standard Deviation2,333,252
Sample Variance5.4T
Range6.7M
R-Value(0.15)
Mean Square Error5.7T
R-Squared0.02
Significance0.58
Slope(80,156)
Total Sum of Squares76.2T

Arbutus Short Term Debt History

20241.6 M
2023850 K
2022744 K
2021766 K
2020780 K
2018340 K
2017M

About Arbutus Biopharma Financial Statements

Arbutus Biopharma shareholders use historical fundamental indicators, such as Short Term Debt, to determine how well the company is positioned to perform in the future. Although Arbutus Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Arbutus Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Arbutus Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Short Term Debt850 K1.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.